&w=3840&q=100)
Glenmark set to launch blood cancer treatment drug Brukinsa in India
Brukinsa, developed by global oncology company BeOne Medicines (formerly BeiGene), is an orally available Bruton's tyrosine kinase (BTK) inhibitor designed to treat multiple types of B-cell blood cancers. It is the first and only BTK inhibitor approved in India for five types of B-cell malignancies.
Approved in over 70 countries
Brukinsa has already been approved in more than 70 countries, with clinical efficacy demonstrated through trials such as ALPINE, ASPEN and SEQUOIA. Its entry into the Indian market addresses a critical need for new and effective blood cancer treatments.
The drug offers a unique pharmacological profile with high response rates and durable disease control across multiple B-cell malignancies. It allows a flexible dosing schedule—once or twice daily—tailored to patient needs.
In the ALPINE trial for relapsed or refractory chronic lymphocytic leukaemia (CLL), Brukinsa showed a lower incidence of serious cardiac side effects compared to ibrutinib, a widely used targeted therapy. Fewer patients discontinued Brukinsa due to heart-related complications.
"We look forward to bringing Brukinsa to India in the coming months as part of our ongoing partnership with BeiGene (now BeOne Medicines)," said Alok Malik, President and Business Head – India Formulations, Glenmark Pharmaceuticals.
'This launch marks a significant milestone in our innovative oncology portfolio, offering patients in India access to a globally trusted therapy with proven efficacy and safety. It underscores Glenmark's ongoing commitment to providing effective and advanced treatments for patients with haematological malignancies," he added.
Global partnership expands to India
Adam Roach, Senior Vice President and Head of the Japan and Asia Pacific region at BeiGene, commented: 'The introduction of Brukinsa in India marks an important step in our ongoing mission to expand patient access to innovative oncology treatments across the Asia Pacific region.'
'We are proud to support Glenmark in bringing this therapy to patients in India, furthering our shared commitment to improve healthcare outcomes globally,' he said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
4 hours ago
- Business Standard
Glenmark Q1 profit tanks 86% on US settlement hit; revenue stays flat
Glenmark Pharmaceuticals reported an 86 per cent year-on-year decline in consolidated net profit to ₹46.8 crore for the first quarter of FY26. Revenue from operations rose marginally by 0.6 per cent to ₹3,264 crore. Sequentially, profit jumped 917 per cent, while revenue was up 0.2 per cent. The sharp profit fall was due to a provision of $37.75 million made by Glenmark to settle a US antitrust and consumer protection lawsuit with a putative direct purchaser class, subject to court approval. Excluding this, profit before tax and exceptional expenses stood at ₹418.8 crore, down 9.4 per cent year-on-year compared with ₹462 crore last year. Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals, said: 'The recent IGI–AbbVie global licensing agreement for ISB 2001 is a strong validation of our innovation capabilities. We remain confident in our strategy to drive growth across our markets while advancing our branded, specialty, and innovative products.' The results were announced after market hours. Glenmark's stock rose 0.6 per cent to end the day at ₹2,043.95 per share on the BSE. The North America business posted revenue of ₹778 crore for the quarter, down 0.3 per cent year-on-year. Sequentially, it recorded 8.9 per cent growth, driven by market share gains in injectable product launches and partnered products. Revenue from emerging markets stood at ₹572.1 crore, marginally higher than ₹570.8 crore in the same period last year, registering a 0.2 per cent year-on-year increase. The company continues to expect double-digit growth on a constant currency basis. In the European market, revenue was ₹667.8 crore compared with ₹695.7 crore in the same period last year, marking a 4 per cent decline.
Mint
6 hours ago
- Mint
Swiss gold industry warns against Swatch bosss US gold tax proposal
ZURICH, - Switzerland's gold industry on Thursday voiced scepticism about a proposal by the boss of watchmaker Swatch to introduce a levy on gold exports to the United States in retaliation for U.S. tariffs on Switzerland. U.S. President Donald Trump last week imposed tariffs of 39% on imported Swiss goods, causing shock and dismay in the Alpine republic, a major refining and transit hub for gold. The U.S. Customs and Border Protection afterwards said Washington might put tariffs on the most widely-traded gold bullion bars in the United States. However, Trump said on Monday that gold would not face tariffs. Swatch CEO Nick Hayek told Swiss newspaper Blick that Trump's announcement indicated that tariffs on gold would be painful for the U.S. president. "Now is the time to go on the offensive. Switzerland should order a 39% export tax on gold bars for the United States," Hayek told the paper. "That's where we have to get at him. That's his Achilles' heel." The Swiss Association of Manufacturers and Traders in Precious Metals said that while ideas to better balance bilateral trade were welcome, careful consideration needed to be given to Switzerland's longer-term interests. "An export tax on Swiss gold destined for the USA would not only harm Switzerland economically, but also damage the reputation of a country that has consistently promoted and defended free trade," ASFCMP President Christoph Wild said. The Swiss Economy Ministry declined to comment on the proposal, but said the support of business representatives was in general welcome and helped underscore the close economic ties between the U.S. and Switzerland. Trump justified his 39% tariff by pointing to Switzerland's sizeable trade surplus with the United States. Part of that is due to gold exports. Hayek said that even if a gold levy failed to move Trump, it would cut the U.S. trade deficit with Switzerland. "If Trump doesn't give in to our pressure, we'll at least improve the trade balance with the U.S. if the Americans no longer import gold bars via Switzerland," he told Blick. Switzerland is continuing to hold talks with U.S. officials aimed at lowering the U.S. tariffs.
Economic Times
9 hours ago
- Economic Times
Swiss gold industry warns against Swatch boss's US gold tax proposal
Synopsis Following U.S. tariffs on Swiss goods, Swatch CEO Nick Hayek proposed a retaliatory export tax on Swiss gold bars destined for the United States. However, the Swiss Association of Manufacturers and Traders in Precious Metals expressed skepticism, fearing economic harm and damage to Switzerland's reputation as a free trade advocate. Reuters Gold bullion bars (file photo) Switzerland's gold industry on Thursday voiced skepticism about a proposal by the boss of watchmaker Swatch to introduce a levy on gold exports to the United States in retaliation for U.S. tariffs on Switzerland. U.S. President Donald Trump last week imposed tariffs of 39% on imported Swiss goods, causing shock and dismay in the Alpine republic, a major refining and transit hub for gold. The U.S. Customs and Border Protection afterwards said Washington might put tariffs on the most widely-traded gold bullion bars in the United States. However, Trump said on Monday that gold would not face tariffs. Swatch CEO Nick Hayek told Swiss newspaper Blick that Trump's announcement indicated that tariffs on gold would be painful for the U.S. president. "Now is the time to go on the offensive. Switzerland should order a 39% export tax on gold bars for the United States," Hayek told the paper. "That's where we have to get at him. That's his Achilles' heel." The Swiss Association of Manufacturers and Traders in Precious Metals (ASFCMP) said that while ideas to better balance bilateral trade were welcome, careful consideration needed to be given to Switzerland's longer-term interests. "An export tax on Swiss gold destined for the USA would not only harm Switzerland economically, but also damage the reputation of a country that has consistently promoted and defended free trade," ASFCMP President Christoph Wild said. The Swiss Economy Ministry declined to comment on the proposal, but said the support of business representatives was in general welcome and helped underscore the close economic ties between the U.S. and Switzerland. Trump justified his 39% tariff by pointing to Switzerland's sizeable trade surplus with the United States. Part of that is due to gold exports. Hayek said that even if a gold levy failed to move Trump, it would cut the U.S. trade deficit with Switzerland. "If Trump doesn't give in to our pressure, we'll at least improve the trade balance with the U.S. if the Americans no longer import gold bars via Switzerland," he told Blick. Switzerland is continuing to hold talks with U.S. officials aimed at lowering the U.S. tariffs.
